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Summary
The vast developmental repertoire of embryonic stem 
cells is well recognised. These primitive stem cells can 
differentiate in vivo and in vitro into cells of all three 
embryonic germ layers (endoderm, mesoderm, ecto-
derm), making them attractive potential agents to target 
for enhanced tissue repair and regeneration. Adult stem 
cells on the other hand are considered more restricted in 
their lineage differentiation capabilities. Recent research 
has challenged this dogma with the finding that bone 
marrow-derived stem cells can differentiate into a wide 
variety of cell types including muscle (skeletal and 
cardiac). Furthermore, although the myocardium has 
for decades been regarded as a post-mitotic organ, a 
series of studies has indicated that a population of stem 
cells exists which is capable of at least partial reconstitu-
tion of the myocardium following an ischaemic insult. It 
is therefore now accepted that adult stem cells could be 
used to enhance myocardial repair. This review discusses 
the current status of adult stem cell research in the light 
of its potential for improving myocardial repair.
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Adult stem cells are defined as cells capable of long-term 
self-renewal while also maintaining their ability to dif-
ferentiate into mature cells with specific morphological and 
functional characteristics (see Table I for a list of stem 
cell definitions). Unlike embryonic stem cells, which are 
characterised by their place of origin (the inner cell mass 
of the blastocyst), adult stem cells have been isolated 
from different adult tissues (such as bone marrow, blood, 
brain, pancreas, fat and skin). As a result, the isolation of 
embryonic stem cells brings with it a significant amount 
of ethical baggage (as a developing embryo must be used 
as the source), something which adult stem cells are not 
lumbered with. While embryonic stem cells are arguably 
more versatile than adult stem cells, too much versatility 
may also have side-effects such as tumour formation. There-
fore, we may find that in the future, adult stem cells become 
the preferred option for stem cell therapy.
Can adult stem cells transdifferentiate into 
cardiomyocytes?
The function of an adult stem cell has previously been 
assumed to be restricted to the tissue from which it is 
derived. However, new evidence suggests that this stem 
cell retains far more plasticity than was once thought. Of 
particular relevance to myocardial repair are the studies 
that demonstrate that multi-potent adult stem cells isolated 
from a variety of tissues are capable of differentiation into 
cardiomyocytes (Table II). These studies have increased the 
potential therapeutic value of adult stem cells in comparison 
to their previously favoured competitors, the embryonic 
stem cells. Furthermore, although long considered to lack 
any regenerative capability, the post-mitotic nature of the 
heart has been called into question. 
Evidence supporting the proliferative ability of human 
adult cardiomyocytes was reported in 1998 by Kajstura et 
al.1 Since then, the mitotic capability of the myocardium 
has been further supported by tracking expression of the 
nuclear protein Ki67 (present only in dividing cells) in the 
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TABLE I. STEM CELL AND PROGENITOR CELL DEFINITIONS
Adult stem cell  An unspecialised cell, derived from a postnatal animal, 
capable of self-renewal AND generating specialised mature 
cells
Hematopoietic A stem cell, which can proliferate and differentiate into 
stem cell mature blood cells.
Mesenchymal A stem cell, which can proliferate and differentiate into
stem cell mesenchymal tissues (such as bone, cartilage, muscle)
Mesodermal   An unspecialised cell capable of yielding mesodermal 
progenitor cell  tissue (such as muscle). Progenitor cells are not capable of 
self-renewal.
Haemangioblast  Earliest mesodermal precursor of both blood and vascular 
endothelial cells.
Angioblast An endothelial cell progenitor cell.
Multipotent adult  Cells isolated from postnatal bone marrow that can 
progenitor cell   differentiate into mesodermal, neuroectodermal and 
endodermal cells in vitro and into all embryonic lineages 
in vivo.
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human heart post-infarct or post-transplant. Mitotic indexes 
of between 0.03% (zone distant from infarct) and 0.08% 
(zone adjacent to infarct) were measured post mortem in 
patients who had died four to 12 days after myocardial 
infarction.2 A mitotic index of 0.9% was also reported in 
the cardiomyocytes of female hearts transplanted into male 
recipients.3 These studies therefore refute the dogma that 
the heart is completely post-mitotic, and provide further 
evidence for the existence of progenitor cells that are capa-
ble of differentiating into mature cardiomyocytes. However, 
the low observed mitotic indexes indicate that, to achieve 
clinical relevance within the setting of repair post-infarct, the 
process would clearly need to be manipulated and enhanced.
How do you heal the modern heart?
There are three basic steps of clinical importance when 
considering the use of adult stem cells to promote tissue 
repair: mobilisation, homing, and differentiation (Fig. 1). 
The environmental signals that stimulate each step are still 
relatively unclear. 
Mobilisation
In response to physiological stress (such as that induced 
during tissue injury), chemokines and cytokines are secreted 
from the affected cells, from immune cells and also from the 
bone marrow. These promote the mobilisation of stem cells 
from the bone marrow, and possibly other stem cell niches, 
into the peripheral circulation. Recent evidence suggests 
that matrix metalloproteinase-9 (MMP-9), stem cell factor 
(SCF) and ckit may play important roles in promoting the 
mobilisation of adult stem cells with cardiomyogenic poten-
tial, making them particularly relevant to myocardial repair.9 
There is therefore evidence that this mobilisation occurs 
following myocardial ischaemia, however the extent may 
be insufficient to substantially promote cardiomyogenesis 
and consequently, fibrosis dominates. Alternatively, the 
circulating stem cells may not be sufficiently attracted to 
the damaged myocardium.
Homing
In 1999 Bittner et al. demonstrated that circulating progeni-
tor cells may home to the heart and act in vivo to replace 
necrotic myocardial tissue.10 The appropriate homing of 
circulating adult stem cells to the myocardium may be 
regulated by a number of receptor–ligand interactions. SCF 
is secreted by macrophages in the damaged myocardium 
and through interaction with its receptor ckit (commonly 
expressed on haematopoietic stem cells and now found to 
be expressed on putative cardiac stem cells), it could attract 
stem cells to the area of injury.11 
Another recent study has found that stromal cell-derived 
factor 1 (SDF-1; a factor which promotes stem cell homing 
to bone marrow) is transiently expressed in the myocardium 
following infarction. The receptor for SDF-1, chemokine 
receptor 4 (CXCR4), is expressed on both haematopoietic 
stem cells and skeletal muscle satellite cells and its expres-
sion is important for the homing of circulating stem cells to 
SDF-positive niches such as the bone marrow and skeletal 
muscle respectively.12-14 Therefore, it is conceivable that 
increased expression of SDF-1 in the damaged myocardium 
could also promote the trafficking of ckit-positive stem cells 
to the myocardial injury site.14
Differentiation
Appropriate environmental and physiological signals are 
required to promote optimal cardiomyocyte differentiation. 
A major concern in the use of stem cells for tissue repair 
is the risk that differentiation may not be 100%. Numerous 
cell models (e.g. embryonic stem cells, bone marrow cells, 
p19 embryonal carcinoma cells) have been used to further 
understand the factors regulating differentiation. Members 
of the transforming growth factor beta (TGFβ) superfamily 
of growth factors,15-17 retinoic acid (RA),18 ascorbic acid19 
and 5-azacytidine,7,20-22 have all been shown to promote 
cardiomyogenesis in vitro. The use of 5-azacytidine on 
rat bone marrow mesenchymal stem cells has however 
subsequently been found to be ineffective unless these cells 
are immortalised, which calls into question the relevance 
of this stimulus (our unpublished data).23 The cardiomyo-
genic stimulation of adult stem cell differentiation prior 
to transplantation may increase the percentage of terminal 
differentiation within the host tissue. However, the regula-
tion of in vitro cardiomyocyte differentiation is still not under-
stood well enough to apply this strategy as a routine therapy.
A landmark investigation by Orlic et al.24 showed that, 
when injected into regions bordering the infarct zone, a 
sub population of bone marrow-derived adult stem cells 
TABLE II. ADULT STEM CELL DIFFERENTIATION INTO 
CARDIOMYOCYTES
Origin of  Stem cell  Route of 
stem cells type Species application Reference
Bone marrow Mesenchymal Rat Transendocardial 4
Bone marrow Mesenchymal Mouse Transendocardial 5
Bone marrow Mesenchymal Rat Systemic 6
Bone marrow Mesenchymal Rat Transendocardial 7
Fat Mesenchymal Rabbit In vitro 8
Peripheral blood CD34 positive Human Intravenous 48
Fig. 1. Clinically important steps during adult 
stem cell transplantation and recruitment to the 
myocardium. EC: endothelial cell; VSMC: vascular 
smooth muscle cell; RA: retinoic acid; SCF: stem 
cell factor; SDF-1: stromal cell-derived factor 1; 
CXCR4: chemokine receptor 4.
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partially enhance the repair of the myocardium following 
infarct. Subsequently there has been a flurry of activity 
within the cardiac stem cell field. 
Current research
Three main approaches have been taken in the quest to 
find the key to optimal myocardial repair (Fig. 2). The first 
relates to an improvement in the recruitment of endogenous 
stem cells, residing either in the bone marrow, the circula-
tion, or in other stem cell niches such as the spleen, liver or 
fat. The second, and perhaps the currently favoured strategy, 
is cell implantation. Cell implantation involves the selection 
and isolation of autologous stem cells from an in vivo 
repository, the expansion of the cells in vitro and then 
the administration of the stem cells into the patient. The 
use of such autologous adult stem cell implantation would 
circumvent the problem of rejection. The third method 
revolves around the identification of resident cardiac stem 
cells and their proliferative stimulation, their migration 
towards, and differentiation within the injured area. Naturally 
for all three strategies the essential role of angiogenesis, 
to repair the damaged vascular supply, should not be 
overlooked, and indeed in many studies the transplanted 
stem cells have been shown to differentiate not only into 
cardiomyocytes, but also into vascular smooth muscle and 
endothelium.1,2 
Recruitment
In the study by Bittner and colleagues (mentioned above), 
healthy bone marrow cells from a male murine donor were 
transplanted into muscular dystrophic female mice (mdx).10 
Y-chromosome-positive cardiomyocytes were subsequently 
found in the heart, indicating that endogenous bone marrow 
stem cells can migrate to the heart and differentiate into 
myocardial tissue. Further support that bone marrow-derived 
circulating stem cells can regenerate myocardial tissue was 
provided in a study using side population (SP) stem cells as 
donor cells.25 The SP of bone marrow, isolated on the basis 
of their ability to extrude Hoechst 33342 (a nuclear dye), is 
a population highly enriched in haematopoietic stem cells, 
which have now been found to contribute to mesenchymal 
tissue repair.25 In the Bittner study, the SP cells were 
transplanted to reconstitute the bone marrow of irradiated 
mice and three months later the myocardium was made 
temporarily ischaemic by left anterior descending artery 
occlusion. SP cells were subsequently found at the edge 
of the myocardial scar and also incorporated into newly 
formed blood vessels. A subsequent study later that year 
indicated that growth factor-stimulated mobilisation of the 
bone marrow could aid in myocardial repair.26 
Mobilisation of lineage-negative (Lin–), ckit-positive 
bone marrow stem cell using granulocyte colony-stimulating 
factor (G-CSF) and SCF increased the survival rate of 
infarcted mice from 17 to 73%.26 Although infarct size in 
surviving mice was similar to that in the controls, a new 
band of myocardium was seen to occupy a large portion of 
the damaged area in the treated animals, and scar formation 
was minimal. No new myocardial tissue was observed in 
the damaged area of the control animals. However, a caveat 
in the experimental protocol used is that the growth factors 
were administered prior to myocardial infarction, calling 
into question the direct therapeutic applicability of the 
findings. Furthermore, even though sufficient mobilisation 
of the stem cells should not be problematic (five million 
bone marrow-derived stem cells can be mobilised following 
several days of G-CSF administration), there is a concern 
that the accompanying increased level of leucocytes could 
potentially destabilise atherosclerotic plaques that probably 
already exist in an infarcted patient.
Cellular transplantation
Cellular cardiomyoplasty using adult stem cells holds 
enormous potential to repair the myocardium. Donor stem 
cells that have been most commonly used are derived 
from the bone marrow, but progenitor cells from skeletal 
muscle27-30 and embryonic stem cells31,32 have also been 
employed. A critical step in cellular transplantation is 
determining an efficient method of delivery. Intravenous 
delivery, although less invasive, may not be able to target 
sufficient stem cells to the damaged area. Intracoronary 
delivery has been used successfully in humans, however 
cells must be administered slowly to prevent cell clumping 
and embolism.43,46 Transendocardial administration (into 
myocardial tissue bordering the infarct), although invasive, 
has also been shown to be successful in numerous animal 
models as well as in humans, and may be the way forward 
as this type of strategy delivers cells directly into the 
cardiomyogenic milieu (Table III).44,45 However, direct injec-
tion into the avascular fibrotic area would in all likelihood 
not favour cardiomyogenesis and therefore this therapeutic 
approach may require pre-programmed differentiation of 
the stem cells down the cardiomyocyte lineage prior to 
implantation.
In 1999 Tomita and co-workers showed that mesenchy-
mal bone marrow cells, which had been differentiated 
into myotubes using 5-azacytidine, stimulated angiogenesis 
when injected into the scar tissue of a cryo-injured rodent 
heart.7 These injected differentiated cells also decreased left 
ventricular chamber hypertrophy and improved systolic and 
developed pressure, whereas undifferentiated bone marrow 
mesenchymal stem cells did not. This study indicated that, 
when appropriately administered, bone marrow stem cells 
could be incorporated into myocardial tissue and it further 
Fig. 2. Strategies for the use of adult stem cells to 
improve myocardial repair.
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suggested that differentiation into myogenic cells prior to 
transplantation may be advantageous to cardiac function 
post-repair. Further studies have found that injection of 
5-azacytidine-treated bone marrow stem cells as late as three 
weeks post-damage increased the number of cardiomyocyte-
like cells in the injured area.4 However these cells did 
not form gap junctions with host tissue, suggesting that 
in the long-term, complete integration and synchronous 
contraction may not take place.
In 2001, Orlic et al. showed for the first time that lineage-
negative (Lin–), ckit+ bone marrow cells, when injected 
into the myocardium bordering the infarct, can generate 
new myocardium consisting of myocytes, endothelial cells 
and smooth muscle cells. These new cardiomyocytes did 
integrate successfully within the myocardium (judged by 
expression of connexin 43) and the mice displayed an 
improvement in haemodynamic function.24 A more recent 
study supported these findings by demonstrating that both 
cultured bone marrow stromal cells and Lin– bone marrow 
cells can differentiate into cardiomyocytes and endothelial 
cells post-transplantation, and can reduce both infarct size 
and fibrosis.5 
The timing and site of transplantation as well as the 
number and population of bone marrow cells is very impor-
tant to ensure optimal engraftment and cardiac recovery 
(Table III). Two studies have shown that if injected (a) 
too late following myocardial damage and (b) into the scar 
rather than into the myocardial zone bordering the infarcted 
site, bone marrow stem cells will not facilitate significant 
improvements within the scar itself.33,34 However, if injected 
within hours of the infarction into the ischaemic zone, an 
improvement in cardiac function was seen.24,35
Unlike cardiac muscle, it is well known and accepted that 
skeletal muscle contains a population of resident progenitor 
cells (satellite cells) which are normally quiescent but 
can be activated in response to conditions where either 
muscle repair or hypertrophy is required.36 These represent a 
relatively accessible source of adult stem cells for repair and 
have therefore been analysed as a potential source of con-
tractile tissue. However, although successfully transplanted 
and able to improve cardiac function in some studies,27,37 
these cells do not integrate into or electromechanically 
couple with the recipient myocardium38 and do not trans-
differentiate into cardiomyocytes in other studies.39 Hence 
any potential use of satellite cells to repair infarcted 
myocardium is unclear.
Resident stem cells
Given the difficulties experienced in the studies reviewed 
above, the existence of putative cardiac stem cells in the 
myocardium itself has generated much excitement. The first 
indication that the myocardium may harbor progenitor cells 
arose from the studies of Quaini et al. and LaFlamme et al.3,40 
These groups studied human female-to-male transplants and 
used the presence of the Y-chromosome to indicate cells 
of extra-cardiac origin. Although there were discrepancies 
regarding the number of host-derived cardiomyocytes in 
the graft (0.04% vs 18% in the study by the LaFlamme 
and Quaini groups, respectively), these studies did indicate 
that some type of progenitor cells infiltrate the transplanted 
heart. 
A subsequent study determined that a side population 
(SP) of cells exists within the adult heart, which may 
be a resident cardiac stem cell-like population.41 More 
recently, clusters of Lin–, ckit+, stem cell antigen (Sca-1)+ 
and telomerase+ cells have been identified in the heart. The 
presence of these markers further supports the presence of 
resident cardiac stem cells.42 In our own studies, we have 
also detected a small number of ckit+ and MDR1+ cells 
within the infarcted rat myocardium (unpublished data), 
which agrees with the recent report by Urbanek et al.42 
These stem cells could be capable of re-entering the cell 
cycle and contributing to an increase in cardiomyogenesis, 
if stimulated correctly. 
Important insights from clinical trials
A number of small clinical trials are currently underway 
to test the efficacy and safety of using autologous bone 
marrow-derived or circulating stem cells to promote myo-
cardial repair. Whereas the transplantation of skeletal myo-
blasts has resulted in ventricular arrhythmias, preliminary 
data from stem cell trials have not indicated arrhythmia 
to be a problem.43 
The preliminary results of some of the trials (Table IV) 
have suggested a beneficial therapeutic effect of adult stem 
cell transplantation (bone marrow-derived or circulating) 
TABLE III. FINDINGS FROM STUDIES USING TRANSENDOCARDIAL INJECTION OF BONE MARROW STEM CELLS TO IMPROVE 
MYOCARDIAL REPAIR
   Delivery   
Population Species Injection site  (post-infarct) Cell number Effects Reference
Adherent  Rat Scar 21 days 106 Improved myocardial function 7
differentiated 
Adherent Lin– Mouse Border 10 minutes  5 × 104 – 5 × 105  Reduced infarct size and  5
fibrosis
Adherent  Rat Scar 21 days  3 × 106 Myocytes in scar  4
differentiated     No functional studies
Mononuclear cells Swine Border and infarction 1 hour  108 Improved myocardial function 35
Lin–, ckit+ Mouse Border 5 hours 1.5 × 104 – 1 × 105 Improved myocardial function 24
Unfractionated Canine Normal, border and infarction 30 days 2 × 107 No global improvement 34
Unfractionated Sheep Infarction 21 days 422 × 106 No engraftment 33
     No global improvement 
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with no apparent adverse side-effects. However it must be 
emphasised that these results have been generated from 
short-term, non-randomised trials with low patient numbers. 
Furthermore, in human studies, proof of transdifferentiation 
of injected stem cells is lacking. It is therefore too early to 
draw landmark conclusions.
Transdifferentiation versus facilitation
Although many animal studies have shown that adult stem 
cells do transdifferentiate into cardiomyocytes, whether they 
act entirely of their own accord to bring about myocardial 
improvement is unclear. In the majority of cases, researchers 
have reported a significant increase in angiogenesis in 
 addition to the differentiation into cardiomyocytes.7,10,24,25 
Newly formed endothelial cells could play an important 
supporting function by acting as a paracrine signaling 
pathway to promote mitosis and differentiation of stem 
cells post-damage. Furthermore, new blood vessels could 
provide an additional supply of blood-borne stem cells. 
In human studies, investigators have also demonstrated an 
increase in angiogenesis.34,47,49 In these studies, the injected 
stem cells were not tagged, making it difficult to establish 
firstly, that they indeed had differentiated and secondly, a 
cause–effect relationship between the stem cells and cardiac 
improvement. 
Conclusion and cautionary remarks
The use of adult stem cells to promote repair following an 
ischaemic insult to the myocardium holds much promise. 
Animal studies have proven the validity of using adult 
stem cells to improve myocardial repair post-infarct. An 
obvious significant advantage of adult stem cells is the 
potential of autologous transplantation, thereby preventing 
host rejection. Studies using bone marrow stem cells have 
not reported any neoplasias, an adverse effect which may 
occur with other stem cell types. It should also be added 
that stem cell therapy is not limited to the treatment of 
ischaemic cardiac disease. Non-ischaemic cardiomyopathy 
may also be treated by stem cells. Cell transplantation 
experiments have been carried out in animal models of 
cardiac diseases (such as dilated cardiomyopathy) and have 
been shown to improve myocardial performance and to 
limit ventricular dilatation.50 The number of experiments 
carried out in animals and humans with non-ischaemic 
cardiomyopathy is limited, but they do provide promising 
preliminary data.
From the successful small number of non-randomised 
clinical trials, it is reasonable to conclude that the use of 
bone marrow or circulating adult stem cells is safe, at least 
in the short-term. However, both experimental and clinical 
studies are still required to determine what the optimal cell 
source, the cell number, the delivery route, the timing of 
delivery and also the long-term safety implications are. 
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Comment
While debate about the use of embryonic stem cell therapy is waged in political, ethical and scientific 
circles, Niesler provides a highly topical, succinct review of the potential uses of the less emotive adult stem 
cells in promoting myocardial repair of ischaemic damage. Evidence is presented that challenges long-held 
views that adult stem cells are limited in their potential to differentiate into specialised cells, and specifically 
addresses the ability of selected cells to differentiate into cardiomyocytes. It also questions the tenet that 
the heart lacks a reservoir of cells capable of self-renewal and highlights the exciting prospect of the use of 
adult stem cells in autologous transplantation, thereby circumventing rejection.
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